InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1728328
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
InMed Pharma filed an 8-K, check for updates.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on September 26, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of these events or any financial figures within the provided text.
Why It Matters
This 8-K filing indicates that InMed Pharmaceuticals Inc. has made a regulatory submission, which could contain important updates for investors regarding company events or financial status.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific material events or financial data that would indicate a high-risk situation.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer
- September 26, 2024 (date) — Date of earliest event reported
- 001-39685 (company) — Commission File Number
- 98-1428279 (company) — IRS Employer Identification No.
- Vancouver, B.C. (location) — Principal Executive Offices
FAQ
What specific events are being reported in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' or 'Financial Statements and Exhibits' being reported.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on September 26, 2024.
What is the company's commission file number?
The company's commission file number is 001-39685.
Where are InMed Pharmaceuticals Inc.'s principal executive offices located?
InMed Pharmaceuticals Inc.'s principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C., Canada.
What is the standard industrial classification for InMed Pharmaceuticals Inc.?
The standard industrial classification for InMed Pharmaceuticals Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-09-26 16:10:58
Filing Documents
- ea0215833-8k_inmed.htm (8-K) — 28KB
- ea021583301ex99-1_inmed.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001213900-24-082247.txt ( ) — 252KB
- inm-20240926.xsd (EX-101.SCH) — 3KB
- inm-20240926_def.xml (EX-101.DEF) — 26KB
- inm-20240926_lab.xml (EX-101.LAB) — 33KB
- inm-20240926_pre.xml (EX-101.PRE) — 22KB
- ea0215833-8k_inmed_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On September 26, 2024, InMed Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2024 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval ("SEDAR") in Canada. The information set forth in this Item 7.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No Description 99.1 SEDAR filing submitted September 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: September 26, 2024 By: /s/ Eric A. Adams Eric A. Adams President and CEO 2